Literature DB >> 19246552

Osteoarticular tuberculosis in patients with systemic lupus erythematosus.

B Hodkinson1, E Musenge, M Tikly.   

Abstract

BACKGROUND: Systemic lupus erythematosus (SLE) patients are at increased risk of developing tuberculosis (TB), particularly extrapulmonary TB (ExP-TB). AIM: The present study was undertaken to investigate whether SLE patients showed increased susceptibility to develop osteoarticular TB (OA-TB). DESIGN AND METHODS: We retrospectively reviewed and compared the frequency of ExP-TB, in particular OA-TB, in patients with SLE at a tertiary hospital in South Africa, to a non-SLE control TB group seen at the same hospital.
RESULTS: TB was diagnosed 111 times in 97 (17%) of the 568 SLE patients. The relative frequency of ExP-TB in the SLE group (25.2%) was significantly lower than in the control group (38.5%) (OR = 1.9, P = 0.006). In contrast, OA-TB was diagnosed in the SLE group in nine (8.1%) patients (seven with peripheral arthritis and two with TB spine) compared to 54 (0.4%) in the overall control group (OR = 20.8, P < 0.001) and 13 (0.2%) in the subgroup of known HIV positive patients in the control group (OR = 44.4, P < 0.001). Within the SLE group, Black ethnicity (P = 0.003), lymphopaenia (P = 0.001), C3/C4 hypocomplementaemia (P = 0.05), corticosteroids [maximum dose (P = 0.002) and duration of treatment (P = 0.02)] and immunosuppressive agents (P = 0.02) were risk factors for TB. Duration of corticosteroid therapy was the only risk factor for OA-TB (P = 0.04).
CONCLUSION: While the relative frequency of ExP-TB was lower in the SLE group compared to the control group, our findings suggest that SLE patients are at particular risk of developing OA-TB. Further prospective studies are needed to better understand the mechanisms that predispose SLE patients to OA-TB.

Entities:  

Mesh:

Year:  2009        PMID: 19246552     DOI: 10.1093/qjmed/hcp015

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  8 in total

1.  Factors associated with active tuberculosis in Colombian patients with systemic lupus erythematosus: a case-control study.

Authors:  Luis Alonso González-Naranjo; Jaime Alberto Coral-Enríquez; Mauricio Restrepo-Escobar; Carlos Horacio Muñoz-Vahos; Daniel Jaramillo-Arroyave; Adriana Lucía Vanegas-García; Ruth Eraso; Gloria Vásquez; Fabián Jaimes
Journal:  Clin Rheumatol       Date:  2020-06-11       Impact factor: 2.980

2.  The impact of TB and HIV on rheumatic conditions: a reminder from the developing world.

Authors:  Maria Mouyis
Journal:  Clin Rheumatol       Date:  2014-03-08       Impact factor: 2.980

3.  Primary Sjogren's syndrome with tuberculous arthritis of left knee.

Authors:  Ting Zhang; Jia Cong; Dong Xu; Xiaomei Leng; Fengchun Zhang
Journal:  BMJ Case Rep       Date:  2011-09-28

4.  The diagnostic utility of the anti-CCP antibody test is no better than rheumatoid factor in South Africans with early rheumatoid arthritis.

Authors:  Bridget Hodkinson; Pieter W A Meyer; Eustasius Musenge; Mahmood M T Ally; Ahmed A Wadee; Ronald Anderson; Mohammed Tikly
Journal:  Clin Rheumatol       Date:  2010-02-02       Impact factor: 2.980

5.  Tuberculous monoarthritis of the wrist in a patient with systemic lupus erythematosus: a case report.

Authors:  W A N V Luke; M P M L Gunathilake; Duminda Munidasa; Dilshan Munidasa; S T De Silva
Journal:  BMC Res Notes       Date:  2017-07-28

6.  Incidence and prevalence of tuberculosis in systemic lupus erythematosus patients: A systematic review and meta-analysis.

Authors:  Qian Wu; Yang Liu; Wei Wang; Yu Zhang; Kui Liu; Song-Hua Chen; Bin Chen
Journal:  Front Immunol       Date:  2022-07-22       Impact factor: 8.786

7.  Spectrum of infections and outcome among hospitalized South Africans with systemic lupus erythematosus.

Authors:  Thozama Dubula; Girish M Mody
Journal:  Clin Rheumatol       Date:  2014-12-23       Impact factor: 3.650

8.  HIV Infection and Osteoarticular Tuberculosis: Strange Bedfellows.

Authors:  B Hodkinson; N Osman; S Botha-Scheepers
Journal:  Case Rep Rheumatol       Date:  2016-05-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.